{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T23:06:04Z","timestamp":1771455964130,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.pbb.2014.04.012","type":"journal-article","created":{"date-parts":[[2014,5,2]],"date-time":"2014-05-02T04:34:44Z","timestamp":1399005284000},"page":"299-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users"],"prefix":"10.1016","volume":"122","author":[{"given":"Jermaine D.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Madera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2014.04.012_bb0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.drugalcdep.2006.09.012","article-title":"Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users","volume":"88","author":"Alho","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"Suppl. 1","key":"10.1016\/j.pbb.2014.04.012_bb0015","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1080\/10550490490440780","article-title":"French field experience with buprenorphine","volume":"13","author":"Auriacombe","year":"2004","journal-title":"Am J Addict"},{"issue":"1","key":"10.1016\/j.pbb.2014.04.012_bb0020","first-page":"95","article-title":"Abuse liability of buprenorphine\u2014a study among experienced drug users","volume":"42","author":"Bedi","year":"1998","journal-title":"Indian J Physiol Pharmacol"},{"key":"10.1016\/j.pbb.2014.04.012_bb0025","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1086\/508184","article-title":"Buprenorphine use: the international experience","volume":"43","author":"Carrieri","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.pbb.2014.04.012_bb0030","doi-asserted-by":"crossref","first-page":"492","DOI":"10.47102\/annals-acadmedsg.V35N7p492","article-title":"Abuse and prescription buprenorphine, regulatory controls","volume":"35","author":"Chua","year":"2006","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.pbb.2014.04.012_bb0045","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/jpet.102.038141","article-title":"Self-administration of intravenous buprenorphine and the buprenorphine\/naloxone combination by recently detoxified heroin abusers","volume":"303","author":"Comer","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2014.04.012_bb0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s002130050956","article-title":"Comparison of intravenous and intranasal heroin self-administration by morphine-maintained humans","volume":"143","author":"Comer","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2014.04.012_bb0060","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1124\/jpet.105.090423","article-title":"Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals","volume":"315","author":"Comer","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2014.04.012_bb0065","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.npp.1301479","article-title":"Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers","volume":"33","author":"Comer","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2014.04.012_bb0055","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1360-0443.2009.02843.x","article-title":"Abuse liability of intravenous buprenorphine\/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers","volume":"105","author":"Comer","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2014.04.012_bb0075","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-010-1898-4","article-title":"Acute effects of intramuscular and sublingual buprenorphine and buprenorphine\/naloxone in non-dependent opioid abusers","volume":"211","author":"Duke","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2014.04.012_bb0095","first-page":"191","article-title":"Superanova accessible general linear modeling","volume":"63","author":"Gagnon","year":"1990","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.pbb.2014.04.012_bb0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000104883","article-title":"Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration","volume":"13","author":"Hakansson","year":"2007","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.pbb.2014.04.012_bb0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.pbb.2014.04.012_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.drugpo.2010.10.004","article-title":"The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia","volume":"22","author":"Horyniak","year":"2011","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.pbb.2014.04.012_bb0115","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2014.04.012_bb0120","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1360-0443.2004.00958.x","article-title":"Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?","volume":"100","author":"Jenkinson","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2014.04.012_bb0125","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.07.019","article-title":"Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians","volume":"120","author":"Johanson","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pbb.2014.04.012_bb0130","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0376-8716(03)00060-7","article-title":"Buprenorphine: how to use it right","volume":"70","author":"Johnson","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"5\u20136","key":"10.1016\/j.pbb.2014.04.012_bb0135","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/FBP.0b013e3283641c3d","article-title":"A review of human drug self-administration procedures","volume":"24","author":"Jones","year":"2013","journal-title":"Behav Pharmacol"},{"issue":"4","key":"10.1016\/j.pbb.2014.04.012_bb0145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00008877-199000140-00003","article-title":"Models of relative reinforcing efficacy of drugs and their predictive utility","volume":"1","author":"Katz","year":"1990","journal-title":"Behav Pharmacol"},{"issue":"3","key":"10.1016\/j.pbb.2014.04.012_bb0150","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0022-3565(25)20504-3","article-title":"The reinforcing and subjective effects of morphine in post-addicts: a dose-response study","volume":"259","author":"Lamb","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2014.04.012_bb0155","first-page":"919","article-title":"Tackling Subutex abuse in Singapore","volume":"47","author":"Lee","year":"2006","journal-title":"Singapore Med J"},{"issue":"1\u20132","key":"10.1016\/j.pbb.2014.04.012_bb0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(01)00591-9","article-title":"Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man","volume":"217","author":"Lindhardt","year":"2001","journal-title":"Int J Pharm"},{"issue":"11","key":"10.1016\/j.pbb.2014.04.012_bb0170","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/ntr\/ntr115","article-title":"Differences in cigarette smoking behaviors among heroin inhalers versus heroin injectors","volume":"13","author":"Liu","year":"2011","journal-title":"Nicotine Tob Res"},{"issue":"4","key":"10.1016\/j.pbb.2014.04.012_bb0175","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF03189469","article-title":"Plasma concentration and disposition of buprenorphine after intravenous and intramuscular doses to baboons","volume":"5","author":"Lloyd-Jones","year":"1980","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.pbb.2014.04.012_bb0180","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"16","author":"Mattick","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.pbb.2014.04.012_bb0185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1521-0391.2009.00008.x","article-title":"Indicators of buprenorphine and methadone use and abuse: what do we know?","volume":"19","author":"Maxwell","year":"2010","journal-title":"Am J Addict"},{"key":"10.1016\/j.pbb.2014.04.012_bb0195","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1126\/science.7352279","article-title":"Buprenorphine suppresses heroin use by heroin addicts","volume":"207","author":"Mello","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.pbb.2014.04.012_bb0200","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0376-8716(85)90062-6","article-title":"Behavioral pharmacology of buprenorphine","volume":"14","author":"Mello","year":"1985","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pbb.2014.04.012_bb0205","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0022-3565(25)33287-8","article-title":"Buprenorphine effects on human heroin self-administration: an operant analysis","volume":"223","author":"Mello","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2014.04.012_bb0190","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0022-3565(25)33600-1","article-title":"Comparison of buprenorphine and methadone effects on opiate self-administration in primates","volume":"225","author":"Mello","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.pbb.2014.04.012_bb0210","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1360-0443.2011.03424.x","article-title":"The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine\/naloxone tablets in opioid abusers","volume":"106","author":"Middleton","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2014.04.012_bb0230","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1360-0443.2006.01731.x","article-title":"Concurrent buprenorphine and benzodiazepine use and self-reported opioid toxicity substitution treatment","volume":"102","author":"Nielsen","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2014.04.012_bb0225","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/pds.2263","article-title":"Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey","volume":"21","author":"Nordmann","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.pbb.2014.04.012_bb0235","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1360-0443.2001.96226710.x","article-title":"Injecting misuse of buprenorphine among French drug users","volume":"96","author":"Obadia","year":"2001","journal-title":"Addiction"},{"issue":"1\u20132","key":"10.1016\/j.pbb.2014.04.012_bb0240","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.drugalcdep.2008.03.025","article-title":"Buprenorphine in primary care: risk factors for treatment injection and implications for clinical management","volume":"97","author":"Roux","year":"2008","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"10.1016\/j.pbb.2014.04.012_bb0245","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.addbeh.2008.07.018","article-title":"Buprenorphine sniffing as a response to inadequate care in substituted patients: results from the Subazur survey in south-eastern France","volume":"33","author":"Roux","year":"2008","journal-title":"Addict Behav"},{"key":"10.1016\/j.pbb.2014.04.012_bb0250","series-title":"SPSS 18.0.0 for windows","author":"SPSS I","year":"2009"},{"key":"10.1016\/j.pbb.2014.04.012_bb0260","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s002130050199","article-title":"The effects of buprenorphine in buprenorphine-maintained volunteers","volume":"129","author":"Strain","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pbb.2014.04.012_bb0255","series-title":"Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586 Findings)","author":"Substance Abuse and Mental Health Services Administration","year":"2010"},{"key":"10.1016\/j.pbb.2014.04.012_bb0265","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/01.jcp.0000138766.15858.c6","article-title":"Effects of high-dose intravenous buprenorphine in experienced opioid abusers","volume":"24","author":"Umbricht","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pbb.2014.04.012_bb0270","author":"United Nations Office on Drugs and Crime"},{"key":"10.1016\/j.pbb.2014.04.012_bb0275","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.drugalcdep.2010.03.014","article-title":"Injection of buprenorphine and buprenorphine\/naloxone tablets in Malaysia","volume":"111","author":"Vicknasingam","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pbb.2014.04.012_bb0280","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0376-8716(02)00312-5","article-title":"Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France","volume":"69","author":"Vidal-Trecan","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pbb.2014.04.012_bb0285","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.pbb.2014.04.012_bb0290","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pbb.2014.04.012_bb0295","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)10510-7","article-title":"Acute administration of buprenorphine in humans: partial agonist and blockage effect","volume":"274","author":"Walsh","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2014.04.012_bb0300","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1477-7517-7-24","article-title":"Route of administration for illicit prescription opioids: a comparison of rural and urban drug users","volume":"7","author":"Young","year":"2010","journal-title":"Harm Reduction J"},{"key":"10.1016\/j.pbb.2014.04.012_bb0305","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0022-3565(24)36921-6","article-title":"Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers","volume":"282","author":"Zacny","year":"1997","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305714001208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305714001208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T17:07:46Z","timestamp":1746205666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305714001208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":50,"alternative-id":["S0091305714001208"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2014.04.012","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2014.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}